Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai - ...

Prior to ActiGraph, Christine was Head of Scientific Innovation at Biogen Healthcare Solutions, leading the clinical development and validation of Biogen’s digital medicine products (Software as ...

The next VALORANT Night Market will last until the end of February 2024. Here are the details. VALORANT Night Markets offer players an opportunity to buy their favorite cosmetics at a discount. The ...

A major goal for me this year has been to eat more protein. After learning about the benefits, such as building muscle, reducing cravings, supporting the immune system, and boosting metabolism, I knew ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Bio­gen’s in­vestors are grow­ing rest­less. Wednes­day’s third-quar­ter earn­ings call checked most of the box­es for a suc­cess­ful re­port. The com­pa­ny raised its full-year ...

FROM POTATO CHIPS to cereal to pasta, you can find a “high in protein” label slapped on almost anything nowadays. Is that necessary a good thing? Of course, there’s no denying the benefits ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...

Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth Quarterly Leqembi sales reached $67 million, beating estimates Cost cuts to drive high-teen percentage operating income boost ...